These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21079066)

  • 21. Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.
    Kadouch JA; van Rozelaar L; Karim RB; Hoekzema R
    Int J STD AIDS; 2013 Sep; 24(9):685-94. PubMed ID: 23970569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
    Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
    J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
    Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
    HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
    Autar RS; Boyd MA; Wit FW; Ruxrungthams K; Sankote J; Lange J; Cooper DA; Phanuphak P; Burger DM; Reiss P
    Antivir Ther; 2007; 12(8):1265-71. PubMed ID: 18240866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy.
    McComsey G
    AIDS Rev; 2002; 4(3):140-7. PubMed ID: 12416448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
    Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
    AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
    Dieterich DT
    AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
    N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy.
    Brown TT; Chu H; Wang Z; Palella FJ; Kingsley L; Witt MD; Dobs AS
    AIDS; 2007 Aug; 21(13):1731-8. PubMed ID: 17690571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E; McKinnon E; Nolan D
    Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
    Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
    Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
    HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
    Nolan D; Mallal S
    J HIV Ther; 2003 Feb; 8(1):2-6. PubMed ID: 12840707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buffalo hump in HIV patients: surgical management with liposuction.
    Sharma D; Bitterly TJ
    J Plast Reconstr Aesthet Surg; 2009 Jul; 62(7):946-9. PubMed ID: 18468504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondria and HIV infection: the first decade.
    Cossarizza A; Troiano L; Mussini C
    J Biol Regul Homeost Agents; 2002; 16(1):18-24. PubMed ID: 12003168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients.
    Seminari E; Tinelli C; Minoli L; Sacchi P; Filice G; Zocchetti C; Meneghetti G; Bruno R; Maserati R
    Antivir Ther; 2002 Sep; 7(3):175-80. PubMed ID: 12487384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.